Skip to Content
COVID-19 Response and Update
International
Amneal Pharmaceuticals
  • Corporate
  • India
  • About
        • AboutWe challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Voices of Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Program
          • Product Donations
          • National and Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson’s
        • Awards & Recognition
  • Products
        • ProductsWe create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & DevelopmentWe invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • InvestorsBecome an Informed Investor
        • Financial Reports
          • SEC Filings
          • Annual Reports
          • Quarterly & Other Reports
        • Events & Presentations
        • Stock Information
        • Corporate Governance
          • Policies
          • Executive Officers & Directors
          • Board Committees
        • Investor Resources
          • Analysts
          • Investor FAQ
          • Email Alerts
          • Information Request
          • RSS Feeds
  • News
  • Careers
        • CareersHelp make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login

KRONOTEC®

We develop innovative drug delivery technologies

KRONOTEC® technology is an advanced osmotic oral drug delivery system that provides timed, customized, and pulsatile drug release to match the timing of disease symptoms.

Unlike other drug delivery technologies in which extended drug release is based on the body’s pH changes, KRONOTEC® utilizes an osmotic technology for extended drug delivery, resulting in a clean delivery profile unaffected by pH changes from food, gastric transit time, and the impact of other pH-modifying drugs. Many respiratory, CNS, immunology, nephrology, cardiovascular, and gastric diseases result in debilitating and life-threatening events during the night or early morning which require timely drug release for maximum effect.

Placebo Graphic

  1. Stage 1: Drug consists of Placebo Layer, Drug Layer, another smaller Placebo layer, another drug layer and an Osmotoic pump with an Outer layer IR Drug
  2. Stage 2: Top Placebo layer gets released as Osmotic pump expands
  3. Stage 3: Next Drug layer gets released as Osmotic pump expands
  4. Stage 4: Next Placebo layer gets released as Osmotic pump expands

Amneal is developing a product utilizing KRONOTEC technology to treat early morning ADHD symptom control. More than 50% of children afflicted with ADHD are unable to perform routine daily functions in the morning before going to school, resulting in excessive stress to the patient, family chaos, and frequent delays in reaching the school. Amneal’s KRONOTEC technology would be administered to the child at bedtime with drug onset after eight to ten hours to treat ADHD symptoms from early morning to late evening for twelve hours.

8PM Dosing - 7AM Onset of action

  • Privacy Notice
  • Copyright & Legal Disclaimer
  • Web Accessibility
  • Expanded Access Policy
  • NABP DDA Accreditation
  • Linkedin
  • Twitter
  • Facebook
  • Youtube
© 2025 Amneal Pharmaceuticals LLC.
All rights reserved.